FDA's Debra Bowen, the OTC division director, named ODE V deputy director.
This article was originally published in The Tan Sheet
Executive Summary
FDA OTC DIVISION DIRECTOR BOWEN TO ODE V DEPUTY DIRECTOR, succeeding Robert DeLap, MD/PhD, who served in the newly created position for a month before becoming permanent director of the Office of Drug Evaluation V. DeLap assumed the title after former director Michael Weintraub, MD, departed the agency July 3 ("The Tan Sheet" June 8, p. 1). Deputy director positions have been created at FDA to help manage the implementation of the agency's new tasks under the FDA Modernization Act, in addition to other duties.